SARS-CoV-2 RT-qPCR testing of pooled saliva samples: A case study of 824 asymptomatic individuals and a questionnaire survey in Japan
Oba et al.
The finding, in our words
Pooled RT-qPCR of self-collected saliva from 824 asymptomatic employees identified two SARS-CoV-2 positives; one positive was detectable only by an amplification trend without a Ct value. A survey of 471 participants revealed that most would accept regular screening only if free or low-cost, supporting pooled saliva testing as a rapid, efficient, and inexpensive method for frequent large-scale decentralised screening.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Self-collected saliva without additives showed comparable diagnostic performance to nasopharyngeal swabs for SARS-CoV-2 detection, with 87.6% sensitivity and 99.6% specificity. The sample remained stable for 72 hours and was deemed acceptable by both patients and staff, supporting its use in decentralised, patient-centric screening programmes.
A two‑tier decentralised testing strategy using self‑collected saliva pools detected SARS‑CoV‑2 with higher sensitivity than a commercial IVD RT‑qPCR test and enabled identification of asymptomatic cases at lower cost.
Saliva shows promise as a patient-friendly alternative to nasopharyngeal swabs for COVID-19 diagnosis, particularly for decentralised testing, though variability in collection and processing methods affects sensitivity. Standardising protocols could improve reliability and support wider use in decentralised diagnostics.
Capillary blood self-sampling achieved 98.3% agreement with venous samples for SARS-CoV-2 IgG antibodies and 100% for IgA among 60 participants, demonstrating accuracy for vaccine monitoring. Saliva self-collection proved feasible with excellent usability, offering a patient-centric alternative for decentralised immunogenicity assessment.
Generic saliva self-collection devices enabled safe unsupervised home sampling that yielded adequate quantity and quality for SARS-CoV-2 nucleocapsid gene detection, with stability maintained after temperature cycling to simulate summer and winter shipping. This supports a patient-centric decentralised approach to infectious-disease screening without requiring healthcare professionals.